Literature DB >> 15830474

In vitro and in vivo activity of 5-fluorocytosine on Acanthamoeba.

A R Stevens, W D O'Dell.   

Abstract

The results of our studies indicated that the avirulent Neff strain of Acanthamoeba was more susceptible to the activity of the anti-metabolite 5-fluorocytosine (5-FC) than was the virulent A-1 strain or a mouse brain reisolate of this strain, designated A-3. Results of competition experiments in which cultures were exposed simultaneously to 5-FC and either uracil, thymidine, or both uracil and thymidine demonstrated that the drug was directed against both deoxyribonucleic acid and ribonucleic acid in the avirulent strain, whereas ribonucleic acid was mainly affected in the virulent amebas. Concentrations >10 mug of 5-FC per ml were amebicidal to the avirulent strain; lower concentrations of the drug, which only affected growth slightly, significantly impaired the capacity of the cells to spontaneously encyst in stationary-phase cultures. On the other hand, the virulent strains were capable of growing in the presence of 5-FC (40 mug/ml) after an initial period of susceptibility. After a few transfers in growth medium lacking the drug, 5-FC-treated virulent amebas exhibited growth parameters typical of untreated cells. However, after successive subcultures in drug-free medium, 5-FC-treated cells lost their resistance and were again susceptible to the drug. This result suggested that the capacity of the cells to develop resistance resulted from a drug-induced mechanism. Spontaneous encystment, which was normally minimal in stationary-phase A-1 or A-3 cultures, was enhanced in A-3 but not A-1 cultures treated with 5-FC (>30 mug/ml). Results obtained from experiments to determine the effectiveness of 5-FC in protecting mice experimentally infected with either A-1 or A-3 amebas indicated that the clinical usefulness of 5-FC may be limited by the capacity of the amebas to develop resistance.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 15830474      PMCID: PMC444638          DOI: 10.1128/AAC.6.3.282

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Fluorinated pyrimidines.

Authors:  C Heidelberger
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1965

2.  Brain abscesses caused by free-living amoeba probably of the genus Hartmannella in a patient with Hodgkin's disease.

Authors:  B V Jager; W P Stamm
Journal:  Lancet       Date:  1972-12-23       Impact factor: 79.321

3.  Primary amoebic meningoencephalitis.

Authors:  K Anderson; A Jamieson
Journal:  Lancet       Date:  1972-04-22       Impact factor: 79.321

4.  The biochemistry of amoebic encystment.

Authors:  R J Neff; R H Neff
Journal:  Symp Soc Exp Biol       Date:  1969

5.  The influence of growth medium on axenic cultivation of virulent and avirulent Acanthamoeba.

Authors:  A R Stevens; W D O'Dell
Journal:  Proc Soc Exp Biol Med       Date:  1973-06

6.  Pathogenic Naegleria sp.--study of a strain isolated from human cerebrospinal fluid.

Authors:  C G Culbertson; P W Ensminger; W M Overton
Journal:  J Protozool       Date:  1968-05

7.  The Micro-Kolmer complement fixation test in routine screening for soil ameba infection.

Authors:  M Kenney
Journal:  Health Lab Sci       Date:  1971-01

8.  Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism).

Authors:  G Medoff; G S Kobayashi; C N Kwan; D Schlessinger; P Venkov
Journal:  Proc Natl Acad Sci U S A       Date:  1972-01       Impact factor: 11.205

9.  Sensitivity of Hartmannella (Acanthamoeba) to 5-fluorocytosine, hydroxystilbamidine, and other substances.

Authors:  D P Casemore
Journal:  J Clin Pathol       Date:  1970-11       Impact factor: 3.411

10.  In vitro studies with 5-fluorocytosine.

Authors:  S Shadomy
Journal:  Appl Microbiol       Date:  1969-06
View more
  5 in total

1.  Differentiation of Naegleria fowleri from Acanthamoeba species by using monoclonal antibodies and flow cytometry.

Authors:  B M Flores; C A Garcia; W E Stamm; B E Torian
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

2.  In vitro susceptibility of pathogenic Naegleria and Acanthamoeba speicies to a variety of therapeutic agents.

Authors:  R J Duma; R Finley
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

3.  In vitro evaluation of antimicrobial agents on Acanthamoeba sp. and evidence of a natural resilience to amphotericin B.

Authors:  Alexandre Taravaud; Philippe M Loiseau; Sébastien Pomel
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2017-09-08       Impact factor: 4.077

Review 4.  Drugs used for the treatment of cerebral and disseminated infections caused by free-living amoebae.

Authors:  Alexandre Taravaud; Zineb Fechtali-Moute; Philippe M Loiseau; Sébastien Pomel
Journal:  Clin Transl Sci       Date:  2021-03-01       Impact factor: 4.689

Review 5.  Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.

Authors:  Angela Loyse; Françoise Dromer; Jeremy Day; Olivier Lortholary; Thomas S Harrison
Journal:  J Antimicrob Chemother       Date:  2013-06-20       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.